Asset Details
Do you wish to reserve the book?
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls
Do you wish to request the book?
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls
2020
Overview
Pathologic alcohol use affects more than 2 billion people and accounts for nearly 6% of all deaths worldwide. There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of alcohol use disorder, although currently none are FDA approved for this indication. Baclofen, a γ-aminobutyric acid B receptor agonist used for spasticity and pain, received temporary approval for alcohol use disorder in France. Despite effective pharmacotherapies, less than 9% of patients who undergo any form of alcohol use disorder treatment receive pharmacotherapies. Current evidence does not support the use of pharmacogenetic testing for treatment individualization. The objective of this review is to provide knowledge on practice parameters for evidenced-based pharmacologic treatment approaches in patients with alcohol use disorder.
Publisher
Elsevier, Inc,Frontline Medical Communications Inc,Elsevier Limited
Subject
/ Acamprosate - administration & dosage
/ Acamprosate - adverse effects
/ Adults
/ Alcohol Deterrents - administration & dosage
/ Alcohol Deterrents - adverse effects
/ Anticonvulsants - administration & dosage
/ Anticonvulsants - adverse effects
/ Disulfiram - administration & dosage
/ Disulfiram - adverse effects
/ Drinking of alcoholic beverages
/ Drug use
/ GABA
/ Humans
/ Naltrexone - administration & dosage
/ Naltrexone - adverse effects
/ Patients
